Repurposing an Antioxidant to Kill Mycobacterium tuberculosis by Targeting the 50S Subunit of the Ribosome
Biomolecules · 2023
DOI: 10.3390/biom13121793 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Wenqi Dong und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program, the Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Tuberculosis and drug-resistant TB remain serious threats to global public health. It is urgent to develop novel anti-TB drugs in order to control it. In addition to redesigning and developing new anti-TB drugs, drug repurposing is also an innovative way to develop antibacterial drugs. Based on this method, we discovered SKQ-1 in the FDA-approved drug library and evaluated its anti-TB activity. In vitro, we demonstrated that SKQ-1 engaged in bactericidal activity against drug-sensitive and -resistant Mtb and confirmed the synergistic effects of SKQ1 with RIF and INH. Moreover, SKQ-1 showed a significant Mtb-killing effect in macrophages. In vivo, both the SKQ-1 treatment alone and the treatment in combination with RIF were able to significantly reduce the bacterial load and improve the survival rate of G. mellonella infected with Mtb. We performed whole-genome sequencing on screened SKQ-1-resistant strains and found that the SNP sites were concentrated in the 50S ribosomal subunit of Mtb. Furthermore, we proved that SKQ-1 can inhibit protein translation. In summary, from the perspective of drug repurposing, we discovered and determined the anti-tuberculosis effect of SKQ-1, revealed its synergistic effects with RIF and INH, and demonstrated its mechanism of action through targeting ribosomes and disrupting protein synthesis, thus making it a potential treatment option for DR-TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China.
- The Cooperative Innovation Center for Sustainable Pig Production, Wuhan 430070, China.
- Key Laboratory of Preventive Veterinary Medicine in Hubei Province, Wuhan 430070, China.
- Hubei Hongshan Laboratory, Wuhan 430070, China.
ORCID-Profile: Xiangru Wang
Förderung
- the National Key Research and Development Program
- the Natural Science Foundation of Hubei Province
Zitieren
APA
Dong, W., Wang, G., Bai, Y., Li, Y., Zhao, L., Lu, W., Wang, C., Zhang, Z., Lu, H., Wang, X., Chen, H., & Tan, C. (2023). Repurposing an Antioxidant to Kill Mycobacterium tuberculosis by Targeting the 50S Subunit of the Ribosome. Biomolecules. https://doi.org/10.3390/biom13121793
Vancouver
Dong W, Wang G, Bai Y, Li Y, Zhao L, Lu W, et al. Repurposing an Antioxidant to Kill Mycobacterium tuberculosis by Targeting the 50S Subunit of the Ribosome. Biomolecules. 2023. doi:10.3390/biom13121793
BibTeX
@article{Dong2023,
author = {Dong, Wenqi and Wang, Gaoyan and Bai, Yajuan and Li, Yuxin and Zhao, Liying and Lu, Wenjia and Wang, Chenchen and Zhang, Zhaoran and Lu, Hao and Wang, Xiangru and Chen, Huanchun and Tan, Chen},
title = {Repurposing an Antioxidant to Kill Mycobacterium tuberculosis by Targeting the 50S Subunit of the Ribosome},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13121793}
}
EUVIMED